论文部分内容阅读
近年来,就再生障碍性贫血(再障)的发病原因,各家提出了干细胞异常说、微环境异常说、体液因子缺陷说和免疫缺陷说等理论。治疗措施繁多,除了用雄性激素、肾上腺皮质激素和脾切除之外,现代更在免疫和移植治疗方面进行新的探索,治疗效果提高,预后有所改观。对新的造血剂亦仍在继续努力开拓,1962年以来国外对人体血浆铜兰蛋白进行了临床和实验研究。近几年在日本临床应用该药于再生障碍性贫血的治疗报导颇多,收到了一定的效果。现就铜兰蛋白的临床应用概况作简要综合。
In recent years, the cause of aplastic anemia (aplastic anemia), each put forward the theory of abnormal stem cell, microenvironment abnormality, humoral factor flaw and immunodeficiency theory. In addition to the use of androgens, adrenal cortical hormones and splenectomy, modern research in immunotherapy and transplantation has led to new treatments and improved prognosis. On the new hematopoietic agents are still continuing to work hard to open up, since 1962 on human plasma cerulein clinical and experimental studies. In recent years in Japan, the clinical application of the drug in the treatment of aplastic anemia quite a lot, has received some results. Brief summary of the clinical application of ceruloplasmin.